Generic Developer Seeks FDA Clearance for Wegovy Multi-Dose Pen ANDA

Share

An unidentified generic drug developer is seeking FDA permission to pursue an abbreviated new drug application (ANDA) for five strengths of semaglutide injection using a multi-dose pen, an early regulatory step toward potential generic competition with Novo Nordisk's blockbuster obesity treatment Wegovy.

In a suitability petition filed on behalf of the developer, Lachman Consultants asks FDA to determine that the proposed semaglutide product is eligible for the ANDA pathway, citing Wegovy FlexTouch as the reference-listed drug.

The proposed single-patient-use pen would deliver four doses, with concentrations and total drug content differing from the reference product. According to the petition, the additional strengths would correspond to doses available in Wegovy single-dose injections while preserving the reference product's dosing regimen and conditions of use.

The petition argues that these differences would not introduce a new indication, route of administration or dosage form, and that the proposed product could demonstrate equivalence under FDA's product-specific guidance for semaglutide.

The request comes as generic developers position themselves for eventual competition in the lucrative semaglutide market, although substantial patent and regulatory barriers remain.

FDA's Orange Book lists a key Wegovy drug-substance patent expiring 12/5/2031, with additional listed patents extending into the late 2030s and 2041. Those protections, along with potential patent litigation and device-related requirements, complicate predictions about when generic versions could reach the U.S. market.

Read more